JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12

JP Morgan analyst Joyce Zhou has initiated coverage on Prelude Therapeutics (NASDAQ: PRLD) with an Overweight rating. The firm has set a price target of $12 for the company's stock.